Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production

[September 12, 2024]  (Reuters) - Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.

The investments are part of Lilly's ongoing commitment to expand production, especially for its top-selling diabetes and obesity drugs, Mounjaro and Zepbound, respectively.

The company has committed over $20 billion since 2020 to build and expand its manufacturing facilities in the U.S. and Europe.

The company said it has invested roughly $800 million in its new facility in Kinsale, Ireland, which began manufacturing Lilly's obesity and diabetes medicines last year. Demand for Zepbound has outpaced supply for most of this year.

The rest of the investment will go towards expanding the drugmaker's facility in Limerick, Ireland, which will focus on producing active biologic ingredients for certain drugs, including the Alzheimer's treatment.

Lilly's drug for Alzheimer's received U.S. approval in July and is currently under review with the European and UK health regulators.

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo

Danish rival Novo Nordisk has also invested billions in manufacturing to ramp up supply of its popular weight-loss drug Wegovy, including a $11 billion deal to take over three sites from contract manufacturer Catalent.

In the U.S., Lilly quickly built a market share of around 40% since launching Zepbound in December. Analysts believe that as Lilly increases its manufacturing capacity, the market could be roughly split 50-50 between Lilly and Novo Nordisk by the end of this year.

Some analysts forecast the market for new weight-loss drugs could reach $150 billion annually by the early 2030s.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Janane Venkatraman)

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.